9 known cases. View patent page →
Lilly sued Wockhardt and related entities for infringement of claims 10 and 11 of US 5,023,269. The court entered final judgment for Lilly on March 21, 2011, finding infringement and upholding validity and enforceability. The lead case number was 1:08-cv-1547-TWP-TAB.
Lilly sued Lupin for infringement of US 5,023,269 in the Cymbalta/duloxetine HCl ANDA litigation. The case was dismissed by stipulation/consent order on April 27, 2011, converting Paragraph IV certifications to Paragraph III, with no appeal.
Lilly sued Sun Pharmaceutical for infringement of US 5,023,269. The case was resolved by the April 27, 2011 order/dismissal in the Cymbalta litigation.
Lilly sued Actavis Elizabeth for infringement of US 5,023,269. The case was dismissed by stipulation without prejudice on April 27, 2011.
Lilly sued Impax Laboratories in the S.D. Ind. Cymbalta/duloxetine HCl ANDA litigation over US 5,023,269. The suit was announced on November 18, 2008, and the case was resolved within the April 27, 2011 Cymbalta order/dismissals (not independently confirmed).
Sandoz was named as a defendant in Lilly's 2008 Cymbalta/duloxetine HCl ANDA litigation involving US 5,023,269. The case was resolved by the April 27, 2011 order/dismissals (docket not confirmed).
Cobalt Laboratories was named as a defendant in Lilly's 2008 Cymbalta/duloxetine HCl ANDA litigation involving US 5,023,269. The case was resolved by the April 27, 2011 order/dismissals (docket not confirmed).
Lilly filed a petition against Aurobindo (along with Lupin) on November 24, 2008, in the Cymbalta/duloxetine HCl ANDA litigation involving US 5,023,269. The case was resolved by the April 27, 2011 order/dismissals (docket not confirmed).
S.D. Ind. docket listed on the Google Patents litigation record for US 5,023,269; party details and disposition were not identified in the narrative.